TrialBMJ (Clinical research ed.)2024

Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.

Min He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.